Evidence map›Paper›PMID 36276271›Full record

ArticleJournal of oncology2022

A Machine Learning Workflow of Multiplexed Immunofluorescence Images to Interrogate Activator and Tolerogenic Profiles of Conventional Type 1 Dendritic Cells Infiltrating Melanomas of Disease-Free and Metastatic Patients.

Saraí G De León Rodríguez, Paúl Hernández Herrera, Cristina Aguilar Flores, Vadim Pérez Koldenkova, Adán Guerrero, Alejandra Mantilla, Ezequiel M Fuentes-Pananá, Christopher Wood, Laura C Bonifaz

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Saraí G De León RodríguezUMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Unidad de Investigación Médica en Inmunoquímica, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-2451-0123
Paúl Hernández HerreraLaboratorio Nacional de Microscopía Avanzada, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico.ORCID https://orcid.org/0000-0002-2206-3489
Cristina Aguilar FloresUMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Unidad de Investigación Médica en Inmunología, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-5317-4731
Vadim Pérez KoldenkovaLaboratorio Nacional de Microscopía Avanzada-IMSS, División de Desarrollo de La Investigación, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-9118-8800
Adán GuerreroLaboratorio Nacional de Microscopía Avanzada, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico.ORCID https://orcid.org/0000-0002-4389-5516
Alejandra MantillaServicio de Patología, Hospital de Oncología Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-5085-6216
Ezequiel M Fuentes-PananáUnidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Christopher WoodLaboratorio Nacional de Microscopía Avanzada, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico.ORCID https://orcid.org/0000-0001-7175-7121
Laura C BonifazUMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Unidad de Investigación Médica en Inmunoquímica, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-8482-5648
Mexican Social Security Institute · MXUniversidad Nacional Autónoma de México · MXHospital Infantil de México Federico Gómez · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is the deadliest form of skin cancer. Due to its high mutation rates, melanoma is a convenient model to study antitumor immune responses. Dendritic cells (DCs) play a key role in activating cytotoxic CD8

Identifiers

PMID36276271
PMCPMC9581597
OpenAlexW4304807360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.